Harmony Biosciences Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $2.21B
- P/E (TTM)
- 12.1
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 16, 2026 | Before market open | $261.00M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $215.40M | $0.55 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | $243.80M | $0.38 | $0.57 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $239.50M | $0.87 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $200.50M | $0.68 | $0.92 |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | $184.70M | $0.78 | $1.03 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | $201.30M | $0.85 | $1.08 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 29, 2024 | Before market open | $186.00M | $0.79 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | $172.80M | $0.20 | $1.05 |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 30, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 16, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| net product revenue | full-year 2026 | $1.00B to $1.04B | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Harmony Biosciences filed with the SEC
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Harmony Biosciences Announces Record Q2 2026 Re venue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2026 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Harmony Biosciences PREANNOUNCES Record QuarterLY Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
HARMONY BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2026 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Harmony Biosciences APPOINTS Glenn Reicin as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Harmony Biosciences Strengthens Executive Team with NEW Appointment and ANNOUNCES Additions TO ITS bOARD
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
HARMONY BIOSCIENCES REPORTS STRONG 2025 FINANCIAL RESULTS AND REITERATES 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2026 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG- TERM VALUE CREATION
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2026 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES REPORTS STRONG Q3 2025 FINANCIAL RESULTS; RECENTLY RAISED 2025 REVENUE GUIDANCE TO
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2024 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES PREANNOUNCES STRONG Q3 2025 WAKIX PERFORMANCE; RAISES 2025 REVENUE GUIDANCE
Results of operations · EX-99.1 to Form 8-K
HARMONY BIOSCIENCES PROVIDES UPDATE FROM ITS PHASE 3 RECONNECT STUDY OF ZYN002 IN FRAGILE X SYNDROME
Regulation FD disclosure · EX-99.1 to Form 8-K
HARMONY BIOSCIENCES REPORTS STRONG Q2 2025 FINANCIAL RESULTS AND REAFFIRMS 2025 REVENUE GUIDANCE; ON TRACK TO ANNOUNCE FRAGILE X TOPLINE DATA FROM PHASE 3 REGISTRATIONAL TRIAL IN Q3 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2024 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
HARMONY BIOSCIENCES STRENGTHENS PATENT POSITION
Other events · EX-99.1 to Form 8-K
HARMONY BIOSCIENCES REPORTS STRONG Q1 2025 FINANCIAL RESULTS, HIGHLIGHTS ADVANCEMENT OF ITS PIPELINE AND UPCOMING CATALYSTS, AND REAFFIRMS 2025 REVENUE GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2025 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES APPOINTS BIOTECH LEADER RON PHILIP TO ITS BOARD OF DIRECTORS
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
HARMONY BIOSCIENCES NAMES ADAM ZAESKE AS CHIEF COMMERCIAL OFFICER TO LEAD THE NEXT PHASE OF COMMERCIAL GROWTH AS ITS PORTFOLIO EXPANDS
Executive or director change · Other events · EX-99.1 to Form 8-K
HARMONY BIOSCIENCES REPORTS STRONG 2024 FINANCIAL RESULTS AND REITERATES 2025 NET REVENUE GUIDANCE; HIGHLIGHTS 2025 CATALYSTS IN SLEEP/WAKE AND FRAGILE X SYNDROME DEVELOPMENT PROGRAMS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2025 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES REPORTS STRONG 2024 REVENUES, PROVIDES 2025 REVENUE GUIDANCE AND HIGHLIGHTS KEY PIPELINE CATALYSTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2025 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Copyright © 2024 Harmony Biosciences. All rights reserved.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Copyright © 2024 Harmony Biosciences. All rights reserved.
Regulation FD disclosure · EX-99.1 to Form 8-K
HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY
Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES REPORTS STRONG SECOND QUARTER 2024 FINANCIAL RESULTS AND ADVANCES PITOLISANT HIGH-DOSE PROGRAM TOWARD EXPECTED PDUFA DATE IN 2028
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES REPORTS STRONG FIRST QUARTER FINANCIAL RESULTS AND ACCELERATION OF ITS GROWTH STRATEGY; ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES INTO RARE EPILEPSY
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND BUSINESS UPDATES
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 and Full Year 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE
Results of operations · EX-99.1 to Form 8-K
PETER Anastasiou To Its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K